EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral Expression of FOXP3 in Brazilian Patients with IPEX Syndrome: From FOXP3 Biomarker to Targeted FOXP3 Therapy Within the CNE3I

Leonardo Oliveira Mendonça, Amanda Melato de Oliveira, Sandra Maria Monteiro, Maria Lúcia Carnevale Marin, Danielli Bichuetti-Silva, Ana Luiza Cunha, Paula Lyra, Renata Capeletti Padula, Luma Abou Jokh Espindola, Giovanna Capato Vilero, Joseane Chiabai, Cristina Kokron und 10 weitere

Journal of Human Immunity · 01.05.2026 · 2 (CIS2026)

DOI: 10.70962/cis2026abstract.175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 01.05.2026. Verfasst von Leonardo Oliveira Mendonça und 21 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a monogenic disorder caused by loss-of-function mutations in the FOXP3 gene, which is critical for the development of functional regulatory T cells (Tregs). In IPEX patients, Tregs are unable to inhibit effector T cell proliferation and cytokine production, leading to a loss of peripheral immune tolerance. The disease presents with heterogeneous clinical manifestations, severe early-onset autoimmunity, the classic triad (enteropathy, eczema, and type 1 diabetes), as well as atypical or late-onset symptoms. A clear genotype–phenotype correlation has not been established for IPEX, and immunological assessments that could contribute to the diagnosis are scarce. Therefore, we aim to characterize the peripheral Treg cells in IPEX patients in Brazil through combined quantitative and qualitative flow cytometry analysis. We enrolled 6 male patients with a confirmed IPEX diagnosis (clinical, genetic, and immunological). All patients exhibited autoimmunity (enteropathy: 5/6; arthritis: 3/6; hemolytic anemia: 2/6; type 1 diabetes: 2/6), and allergic manifestations (rhinitis: 6/6; asthma: 4/6), eczema (4/6), and recurrent sinusitis (4/6) were also observed. Up to the last follow-up, two patients were alive after bone marrow transplantation and one after gene therapy (Figure 1). Peripheral FOXP3 expression was assessed in peripheral blood mononuclear cells (PBMCs) by flow cytometry (CD3, CD4, CD25, CD127, and FOXP3). Quantitative analysis determined the frequency of Tregs (CD4+CD25+CD127-FOXP3+), while qualitative analysis measured FOXP3 protein expression via median fluorescence intensity (MFI). The frequency of circulating Tregs in IPEX patients from our cohort was highly variable (14.6%–81.2%; mean: 58.5%) and overlapped with the control range (59.6%–84.1%; mean: 72.4%). In contrast, FOXP3 MFI was significantly lower in patient Tregs (mean: 986, range: 863–1,276) compared to controls (mean: 1,937, range: 1,089–4,132; p<0.05), another indication of quantitative Treg defects. Different patterns of FOXP3 expression have been reported, depending on the type and location of the mutation. While Treg numbers can be preserved in IPEX syndrome, FOXP3 protein expression per cell is consistently and significantly reduced. This defect in the expression level of FOXP3 likely underlies Treg dysfunction and disease pathogenesis. Assessment of FOXP3 MFI emerges as an additional valuable complementary diagnostic tool, providing functional insight beyond genetic sequencing alone. Figure 1. Clinical, immunologic, genetic, and therapeutic findings for IPEX syndrome within the CNE3i (Centro Nacional de Erros Inatos da Imunidade e Imunodesregulação) in Brazil. (1) Demonstrates the main clinical and geographical findings of the six IPEX patients; (2) general and advanced laboratory findings; and (3) genetics and therapeutics. SP, São Paulo; MG, Minas Gerais; PE, Pernambuco; DF, Distrito Federal; ES, Espírito Santo; IgE, immunoglobulin E; IgG immunoglobulin G; DNT, double negative T cells; IFN-SG, interferon-stimulated genes; MFI, median fluorescence intensity; BMT, bone marrow transplantation; GT, gene therapy; LFW, last follow-up. FINEP funding: 0956/24; FAPESP funding: 2023/09965-0; Instituto de Investigação em Imunologia funding CNPQ/MCTI: 408685/2024-7.

Zitieren

APA

Mendonça, L. O., Oliveira, A. M. D., Monteiro, S. M., Marin, M. L. C., Bichuetti-Silva, D., Cunha, A. L., Lyra, P., Padula, R. C., Espindola, L. A. J., Vilero, G. C., Chiabai, J., Kokron, C., Iwashita, M. T., Masiero, L., Dorna, M., Faria-Morais, I., Burgarelli, G., Alexander, J. L. A., Bachetta, R., …, & Carneiro-Sampaio, M. M. (2026). Peripheral Expression of FOXP3 in Brazilian Patients with IPEX Syndrome: From FOXP3 Biomarker to Targeted FOXP3 Therapy Within the CNE3I. Journal of Human Immunity, 2(CIS2026). https://doi.org/10.70962/cis2026abstract.175

Vancouver

Mendonça LO, Oliveira AMD, Monteiro SM, Marin MLC, Bichuetti-Silva D, Cunha AL, et al. Peripheral Expression of FOXP3 in Brazilian Patients with IPEX Syndrome: From FOXP3 Biomarker to Targeted FOXP3 Therapy Within the CNE3I. Journal of Human Immunity. 2026;2(CIS2026). doi:10.70962/cis2026abstract.175

BibTeX
@article{Mendona2026,
  author = {Mendonça, Leonardo Oliveira and Oliveira, Amanda Melato de and Monteiro, Sandra Maria and Marin, Maria Lúcia Carnevale and Bichuetti-Silva, Danielli and Cunha, Ana Luiza and Lyra, Paula and Padula, Renata Capeletti and Espindola, Luma Abou Jokh and Vilero, Giovanna Capato and Chiabai, Joseane and Kokron, Cristina and Iwashita, Márcia Toraiwa and Masiero, Ludmilla and Dorna, Mayra and Faria-Morais, Isabella and Burgarelli, Guilherme and Alexander, Jessie Lee An and Bachetta, Rosa and Freschi-Barros, Samar and Kalil, Jorge and Carneiro-Sampaio, Magda Maria},
  title = {Peripheral Expression of FOXP3 in Brazilian Patients with IPEX Syndrome: From FOXP3 Biomarker to Targeted FOXP3 Therapy Within the CNE3I},
  journal = {Journal of Human Immunity},
  year = {2026},
  volume = {2},
  number = {CIS2026},
  doi = {10.70962/cis2026abstract.175}
}
Kostenlos starten →